DongKoo Bio & Pharma Co., Ltd. Stock: price and insider trades · South Korea
동구바이오제약
No insider purchase over the last 90 days. The latest, by 조용준, was filed 07 Jul 2026.
Who traded when
BuySaleSince the insiders bought
- -15.7%Entry ₩3,780 · Close 27 Oct 2026 ₩3,185
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 10,595,613 sharesKRXDART:20260715000432
- 2,975 sharesKRXDART:20260707000344Canonical exit: 5 Oct 2026 (T+90)
- 3,357 sharesKRXDART:20260629000444Canonical exit: 27 Sept 2026 (T+90)
- ●Executives0DART
- 250 sharesKRXDART:20260605000475Canonical exit: 3 Sept 2026 (T+90)
- 0KRXDART:20260526000383
- 0KRXDART:20260513000598
- 34,000 sharesKRXDART:20260402002932
- ●Executives0DART
- ●Executives0DART
- 950 sharesKRXDART:20260112000417Canonical exit: 5 Apr 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 189,500 sharesShareKRXDART:20250207000565
- 189,500 sharesKRXDART:20250207000550
- 0KRXDART:20241213000118
- 9,915 sharesKRXDART:20241118000336Canonical exit: 9 Feb 2025 (T+90)
- 0KRXDART:20240611000148
25 of 63 declarations
About DongKoo Bio & Pharma Co., Ltd.
At 동구바이오제약 (DongKoo Bio & Pharma Co., Ltd.), a South Korean health care company valued at KRW 91.5 billion, sales weigh more than purchases: 17 sales against 5 purchases, or 23% purchases among open-market trades. No amount is reported.
이경옥, filed as 10%이상주주, has 14 filings, all sales, which is 14 of the record's 17 sales. 조용준 (대량보유자) is the most present filer, with 38 of the 56 filings: 5 purchases and 3 sales. The company 동구바이오제약 itself appears in 3 filings, with neither purchase nor sale; 서정욱 has 1. In all, 34 filings are of another kind.
Read moreShow less
Filings were published from February 26, 2021 to July 15, 2026. It holds 15 filings in 2021, 8 in 2022, 14 in 2023, 4 in both 2024 and 2025, then 11 in 2026. The last twelve months gather 12 of them, including 4 purchases and 2 sales. Publication lags the trade by 7 days at the median.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
